文献速递心律失常冠心病血脂与心血管预防

心房颤动患者抗栓治疗与首次心肌梗死风险

Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

基于丹麦全国登记数据,纳入1997-2012年首次诊断心房颤动且无冠心病史的患者71959例,按时间变化的抗栓治疗分组,用泊松回归估计结局相对风险。与维生素K拮抗剂单药治疗相比,阿司匹林单药和双联治疗与首次心肌梗死风险更高相关,双联治疗出血风险更高。

要点

  • VKA单药治疗与首次MI风险低于ASA单药相关(IRR 1.54)。
  • 双联治疗与MI风险高于VKA单药相关(IRR 1.22)。
  • 双联治疗出血风险显著高于VKA单药(IRR 1.93)。

核心结论

  • VKA单药治疗与首次MI和卒中风险低于ASA单药相关。
  • ASA联合VKA治疗与MI风险降低无关,但与出血风险增加相关。

研究设计与样本

  • 基于丹麦全国行政登记的前瞻性队列研究,纳入1997-2012年首次诊断房颤且无冠心病史患者71959例(中位年龄75岁,女性47%),按时间变化抗栓治疗分组,泊松回归估计相对风险。

主要发现

  • 基线时VKA单药治疗37539例(52%),ASA单药治疗25458例(35%),双联治疗8962例(13%)。
  • MI发生率为3%(n=2275)。
  • 与VKA组相比,MI风险ASA组IRR 1.54(95%CI 1.40-1.68),双联治疗组IRR 1.22(95%CI 1.06-1.40)。
  • 与VKA组相比,出血风险双联治疗组IRR 1.93(95%CI 1.81-2.07)。
  • 与VKA组相比,卒中风险ASA组IRR 2.00(95%CI 1.88-2.12),双联治疗组IRR 1.30(95%CI 1.18-1.43)。

临床怎么用

  • 在房颤患者中,VKA单药治疗与首次MI和卒中风险低于ASA单药相关。
  • ASA联合VKA治疗与MI风险降低无关,且与出血风险增加相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with atrial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infarction (MI). Although it has been established that the efficacy of anticoagulation is superior to that of antiplatelet agents for stroke prophylaxis in AF, the optimal antithrombotic treatment remains uncertain for primary protection against MI. OBJECTIVES: The authors investigated the incidence of first-time MI in patients with AF according to antithrombotic treatment and estimated the risk of stroke and bleeding. METHODS: Subjects with first-time AF diagnosed from 1997 to 2012 without history of coronary artery disease were identified using Danish nationwide administrative registries. Subjects were divided into time varying exposure groups according to antithrombotic treatment. The relative risks of outcomes were estimated by Poisson regression models. RESULTS: A total of 71,959 patients (median 75 years of age; females: 47%). At baseline, 37,539 patients (52%) were treated with vitamin K antagonist (VKA) monotherapy, 25,458 (35%) with acetylsalicylic acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA + ASA). The incidence of MI was 3% (n = 2,275). Relative to the VKA-treated group, the associated risk of MI was significantly higher for ASA (incidence rate ratio [IRR]: 1.54; 95% confidence interval [CI]: 1.40 to 1.68) and dual-therapy (IRR: 1.22; 95% CI: 1.06 to 1.40). The bleeding risk was significantly higher for dual-therapy (IRR: 1.93; 95% CI: 1.81 to 2.07). The risk of stroke relative to that of VKA therapy was significantly higher for both ASA (IRR: 2.00; 95% CI: 1.88 to 2.12) and dual-therapy (IRR: 1.30; 95% CI: 1.18 to 1.43). CONCLUSIONS: VKA monotherapy in patients with AF was associated with a lower risk of first-time MI and stroke than ASA monotherapy. Combination of ASA and VKA therapy was not associated with a lower risk of MI but was associated with increased bleeding risk.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee CJ, Pallisgaard JL, Olesen JB, et al. Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017. PMID: 28619189. doi:10.1016/j.jacc.2017.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。